## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <sup>*</sup> STEINMAN LAWRENCE					2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Pasithea Therapeutics Corp.</u> [KTTA]							onship of Reporting Person(s) to Issuer all applicable) Director 10% Owner				
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 10/17/2022								ve title		specify	
1111 LINCOLN ROAD, SUITE 500					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) MIAMI BEACH FL 33139											X		•	Reporting Person than One Reporti	ng Person	
(City)	(State)	(Zi	p)													
		Та	ble I - Non-	Derivative S	ecurities Acq	uired,	Disp	osed of,	or Ber	efic	ially Ow	ned				
Date			:. Transaction Date Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a				5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
						Code	v	Amount	(A) (D)	or	Price	Transactior (Instr. 3 and			(Instr. 4)	
Common Stock 10/1						Α		1,000			\$1.14	1,263	,174	D		
Common Stock 10/1						A		9,000			\$1.13	1,272,	,174	D		
					urities Acqui ls, warrants, c	•	•				•	ed				
Derivative	2. Conversion or Exercise	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, ar) 4. 5. Number of Derivative 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and A Securities Un Derivative Securities		s Und	erlying	Derivative	9. Numbe derivative Securities	e Ownership	11. Nature of Indirect Beneficial						

Secur		or Exercise Price of Derivative Security	(Month/Day/Year)	if any (Month/Day/Year)	Code (Instr. 8)		Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		(Month/Day/Year)		Derivative Security (Instr. 3 and 4)		Security (Instr. 5)	Owned Following Reported	Direct (D)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)			

Explanation of Responses:

/s/ Larry Steinman

\*\* Signature of Reporting Person

<u>10/17/2022</u> Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.